Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease.

[1]  A. Reuser,et al.  Pompe's disease , 2008, The Lancet.

[2]  R. Sidman,et al.  Temporal Neuropathologic and Behavioral Phenotype of 6neo/6neo Pompe Disease Mice , 2008, Journal of neuropathology and experimental neurology.

[3]  M. O'Callaghan,et al.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. , 2008, Molecular genetics and metabolism.

[4]  T. Taksir,et al.  Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. , 2008, Human gene therapy.

[5]  P. Doorn,et al.  Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease , 2008, Neuromuscular Disorders.

[6]  K. Tsuchida,et al.  Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  C. Vosa,et al.  Long-Term Enzyme Replacement Therapy for Pompe Disease With Recombinant Human Alpha-glucosidase Derived From Chinese Hamster Ovary Cells , 2007, Journal of child neurology.

[8]  R. Werner,et al.  Glycosylation of therapeutic proteins in different production systems , 2007, Acta paediatrica.

[9]  R. Desnick,et al.  Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase A. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  K. Yarema,et al.  Metabolic oligosaccharide engineering: perspectives, applications, and future directions. , 2007, Molecular bioSystems.

[11]  M. Ausems,et al.  Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype , 2007, Neurology.

[12]  B. Byrne,et al.  Recombinant human acid α-glucosidase , 2007, Neurology.

[13]  E. Ralston,et al.  Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  B. Thurberg,et al.  Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease , 2006, Laboratory Investigation.

[15]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[16]  G. Herman,et al.  Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.

[17]  W. Canfield,et al.  Structural Requirements for Efficient Processing and Activation of Recombinant Human UDP-N-acetylglucosamine:Lysosomal-enzyme-N-acetylglucosamine-1-phosphotransferase* , 2006, Journal of Biological Chemistry.

[18]  H. Amthor,et al.  Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. , 2005, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[19]  S. Elliott,et al.  Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.

[20]  N. Raben,et al.  Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. , 2005, The Biochemical journal.

[21]  J. Goldman-Levine,et al.  Insulin Detemir—A New Basal Insulin Analog , 2005, The Annals of pharmacotherapy.

[22]  K. Nagashima,et al.  Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Qun Zhou,et al.  Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid α-Glucosidase Improves the Clearance of Glycogen in Pompe Mice* , 2004, Journal of Biological Chemistry.

[24]  G. Foster.  Pegylated interferons: chemical and clinical differences , 2004, Alimentary pharmacology & therapeutics.

[25]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[26]  W. Sly,et al.  Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[28]  W. Kuzon,et al.  Satellite cell depletion in degenerative skeletal muscle , 2003, Apoptosis.

[29]  R. Brady,et al.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease , 1994, Journal of Inherited Metabolic Disease.

[30]  S. Iida,et al.  Establishment of FUT 8 Knockout Chinese Hamster Ovary Cells : An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity , 2004 .

[31]  M. Koury.  Sugar coating extends half-lives and improves effectiveness of cytokine hormones. , 2003, Trends in biotechnology.

[32]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[33]  B. van den Hazel,et al.  Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[35]  J. Egrie,et al.  Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. , 2003, Experimental hematology.

[36]  L. Buck,et al.  Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.

[37]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[38]  N. Raben,et al.  Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  Qun Zhou,et al.  Mannose 6-phosphate quantitation in glycoproteins using high-pH anion-exchange chromatography with pulsed amperometric detection. , 2002, Analytical biochemistry.

[40]  P. Trainer,et al.  The place of pegvisomant in the management of acromegaly , 2001, Expert opinion on investigational drugs.

[41]  R. Kornfeld,et al.  Purification and Multimeric Structure of BovineN-Acetylglucosamine-1-phosphodiester α-N-Acetylglucosaminidase* , 1998, The Journal of Biological Chemistry.

[42]  H. Reichmann,et al.  Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients , 1998, Neurogenetics.

[43]  K. Felice,et al.  Clinical Variability in Adult‐Onset Acid Maltase Deficiency: Report of Affected Sibs and Review of the Literature , 1995, Medicine.

[44]  W. Kiess,et al.  Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. , 1992, The Journal of clinical endocrinology and metabolism.

[45]  B. Oostra,et al.  Human lysosomal alpha-glucosidase. Characterization of the catalytic site. , 1991, The Journal of biological chemistry.

[46]  K. von Figura,et al.  Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. , 1991, Biochemistry international.

[47]  D. Livingston,et al.  A Modified Human Tissue Plasminogen Activator with Extended Half–Life In Vivo , 1987, Bio/Technology.

[48]  B. Brown,et al.  Glycogen storage disease type IB. , 1983, Archives of pathology & laboratory medicine.

[49]  C. Steer,et al.  Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. , 1981, Biochimica et biophysica acta.